Drug-diagnostics co-development in oncology / topic editor Jan Trøst Jørgensen.
The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
TeilnehmendeR: | |
Place / Publishing House: | France : : Frontiers Media SA,, 2014 |
Year of Publication: | 2014 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 online resource (111 pages) :; colour illustrations, charts. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547926104498 |
---|---|
ctrlnum |
(CKB)3710000000612036 (oapen)https://directory.doabooks.org/handle/20.500.12854/45512 (EXLCZ)993710000000612036 |
collection |
bib_alma |
record_format |
marc |
spelling |
Jan Trost Jorgensen auth Drug-diagnostics co-development in oncology [electronic resource] / topic editor Jan Trøst Jørgensen. Frontiers Media SA 2014 France : Frontiers Media SA, 2014 1 online resource (111 pages) : colour illustrations, charts. text txt rdacontent computer c rdamedia online resource cr rdacarrier text file rda Frontiers Research Topics Includes bibliographical references. The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. English Creative Commons Attribution 4.0 International. CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode Description based on online resource ; title from PDF title page (viewed on 03/30/2021) Unrestricted online access star Oncology. IHC fish precision medicine NGS Drug-diagnostic co-development companion diagnostics oncology personalized medicine Jørgensen, Jan Trøst, editor. |
language |
English |
format |
Electronic eBook |
author |
Jan Trost Jorgensen |
spellingShingle |
Jan Trost Jorgensen Drug-diagnostics co-development in oncology Frontiers Research Topics |
author_facet |
Jan Trost Jorgensen Jørgensen, Jan Trøst, |
author_variant |
j t j jtj |
author2 |
Jørgensen, Jan Trøst, |
author2_variant |
j t j jt jtj |
author2_role |
TeilnehmendeR |
author_sort |
Jan Trost Jorgensen |
title |
Drug-diagnostics co-development in oncology |
title_full |
Drug-diagnostics co-development in oncology [electronic resource] / topic editor Jan Trøst Jørgensen. |
title_fullStr |
Drug-diagnostics co-development in oncology [electronic resource] / topic editor Jan Trøst Jørgensen. |
title_full_unstemmed |
Drug-diagnostics co-development in oncology [electronic resource] / topic editor Jan Trøst Jørgensen. |
title_auth |
Drug-diagnostics co-development in oncology |
title_new |
Drug-diagnostics co-development in oncology |
title_sort |
drug-diagnostics co-development in oncology |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA Frontiers Media SA, |
publishDate |
2014 |
physical |
1 online resource (111 pages) : colour illustrations, charts. |
isbn |
9782889193325 (ebook) |
callnumber-first |
R - Medicine |
callnumber-subject |
RM - Therapeutics and Pharmacology |
callnumber-label |
RM301 |
callnumber-sort |
RM 3301.25 |
illustrated |
Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
615 - Pharmacology & therapeutics |
dewey-full |
615.1/9 |
dewey-sort |
3615.1 19 |
dewey-raw |
615.1/9 |
dewey-search |
615.1/9 |
work_keys_str_mv |
AT jantrostjorgensen drugdiagnosticscodevelopmentinoncology AT jørgensenjantrøst drugdiagnosticscodevelopmentinoncology |
status_str |
c |
ids_txt_mv |
(CKB)3710000000612036 (oapen)https://directory.doabooks.org/handle/20.500.12854/45512 (EXLCZ)993710000000612036 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Drug-diagnostics co-development in oncology |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1797653537910423552 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03199cam a2200481 i 4500</leader><controlfield tag="001">993547926104498</controlfield><controlfield tag="005">20240424225746.0</controlfield><controlfield tag="006">m o j | </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">191103u2014uuuufr a ob u|00-||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9782889193325 (ebook)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000612036</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/45512</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000612036</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">UkMaJRU</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">RM301.25</subfield></datafield><datafield tag="082" ind1="0" ind2="0"><subfield code="a">615.1/9</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jan Trost Jorgensen</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug-diagnostics co-development in oncology</subfield><subfield code="h">[electronic resource] /</subfield><subfield code="c">topic editor Jan Trøst Jørgensen.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2014</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">France :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (111 pages) :</subfield><subfield code="b">colour illustrations, charts.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">Creative Commons Attribution 4.0 International.</subfield><subfield code="f">CC BY 4.0</subfield><subfield code="u">https://creativecommons.org/licenses/by/4.0/legalcode</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on online resource ; title from PDF title page (viewed on 03/30/2021)</subfield></datafield><datafield tag="506" ind1="0" ind2=" "><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Oncology.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IHC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fish</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">precision medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NGS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Drug-diagnostic co-development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">companion diagnostics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jørgensen, Jan Trøst,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-04-26 02:59:59 Europe/Vienna</subfield><subfield code="d">00</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-03-17 15:52:20 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338710390004498&Force_direct=true</subfield><subfield code="Z">5338710390004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338710390004498</subfield></datafield></record></collection> |